Leading with Purpose: ESET Puts Pamela Ong in Command as Singapore's Digital Economy Accelerates
Ong has over a decade of experience at ESET, consistently demonstrating her capability through successive leadership roles including Channel Manager for China, Sales Manager for APAC, and most recently, Sales Director for APAC. Her deep industry knowledge and proven leadership make her uniquely suited to elevate ESET's position in Singapore, a market identified as a pivotal growth hub in the region.
'I'm incredibly proud to take on this role,' said Ong. 'Singapore has quickly emerged as a digital innovation hub, especially after post-COVID digital transformation efforts of Singapore. The demand for advanced protection has thus grown tremendously as businesses accelerate their digital journeys. As we expand ESET's impact across Asia, I'm excited to deepen our presence in Singapore, a market that is both strategic and full of potential. I'm also equally committed to building a more inclusive future where women can thrive in cybersecurity, and helping to shape a stronger, safer digital world for everyone.'
In addition to her business acumen, Ong is also a passionate champion of DEI in cybersecurity and STEM. In 2025, she helped launch the ESET Women in Cybersecurity Scholarship in Singapore and India, empowering the next generation of female cybersecurity professionals and driving change across the industry.
'Singapore is a strategic priority for ESET in the APAC region. It's paramount that we place our best people in our most important roles, and Pamela brings unmatched experience, leadership, and vision to this position,' said Parvinder Walia, President of the Asia Pacific region at ESET.
Ong will be based in Singapore, reporting directly to Walia.
About ESET
ESET® provides cutting-edge digital security to prevent attacks before they happen. By combining the power of AI and human expertise, ESET stays ahead of known and emerging cyberthreats — securing businesses, critical infrastructure, and individuals. Whether it's endpoint, cloud, or mobile protection, our AI-native, cloud-first solutions and services remain highly effective and easy to use. ESET technology includes robust detection and response, ultra-secure encryption, and multifactor authentication. With 24/7 real-time defense and strong local support, we keep users safe and businesses running without interruption. An ever-evolving digital landscape demands a progressive approach to security: ESET is committed to world-class research and powerful threat intelligence, backed by R&D centers and a strong global partner network.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
2 hours ago
- New Straits Times
Pharmaniaga completes regularisation plan, set to exit PN17 by 2026
KUALA LUMPUR: Pharmaniaga Bhd has completed its Practice Note 17 (PN17) regularisation plan following the completion of its capital reduction exercise through the cancellation of RM520 million in issued share capital. In a statement today, the pharmaceutical company said the step firmly sets the group on course to exit the PN17 status latest by the first quarter (1Q) of 2026. "The capital reduction exercise, which involved the cancellation of RM520 million in issued share capital, was completed after confirmation was received today from the Registrar of Companies that all statutory requirements have been fulfilled. "Following the completion of this exercise, the issued share capital of the group is RM249.62 million, comprising 6.55 billion shares," it said. Pharmaniaga fell into PN17 status in February 2023, dragged by its RM552.3 million provision for "slow-moving inventories" of COVID-19 vaccines. At the close of trading today, the counter finished unchanged at 18.5 sen, with 28.69 million shares changing hands.
The Star
6 hours ago
- The Star
Klang Valley to remain mainstay of industrial hubs
Knight Frank Malaysia said that between 2020 and 2024, annual industrial transaction values in the Klang Valley and Johor Baru grew by an 18% and 40% four-year compounded annual growth rate, respectively. PETALING JAYA: Klang Valley will likely remain the largest industrial hub in the country on the back of its relatively more mature industrial parks, infrastructure and strategic access to ports, according to Kenanga Research. Specifically on Johor, the research house gathered that its industrial and data centre boom commenced with the launch of YTL Green Data Centre Park in Kulai in August 2022. This kick-started interests by large multinationals in the state, further fuelling its investments into that space, it noted. The research house said with the officiation of Johor's Forest City Special Financial Zone in September 2024 and Johor-Singapore Special Economic Zone in January 2025, in addition to the increase in cross-border activities with Singapore stemming from the upcoming launch of the Rapid Transit System link, it believes that activities and investments into the state could remain buoyant in the near-to-medium term. According to property consultancy company Knight Frank Malaysia, between 2020 and 2024, annual industrial transaction values in Klang Valley and Johor Baru (including Kulai) grew by an 18% and 40% four-year compounded annual growth rate, respectively. While this could be attributed to pent-up demand coming out of the Covid-19 pandemic, it ties in with the increase of capital investments injected into the mentioned regions, Kenanga Research said. Kenanga Research believes Penang remains a hot spot for industrial activity, mostly dominated by the technology and semiconductor sectors. The brokerage recently co-organised a real estate event with Knight Frank on the property consultancy's exclusive launch of its half-yearly real estate highlights for the first half of 2025. Focusing on high-rise residential trends, Knight Frank highlighted that transaction volumes and values in Kuala Lumpur had picked up mostly in 2022, coming out of the pandemic. Knight Frank found it worth noting as well that the growth of average transaction values had outpaced volumes, reflecting a higher appetite by homebuyers for higher-priced homes. From Kenanga Research's checks among property developers and mortgage lenders, the pick-up in transaction volumes in 2022 could have been made up by more affordable offerings (RM300,000 to RM500,000) which led market launches at that time, owing to development being stalled by the movement control orders between 2020 and 2021. On the data centre front, there was a surge in data centre investments post-Covid-19, with total investment reaching RM160bil in 2024, more than triple the amount in 2023. However, the sector is now entering a more mature execution phase of announced plans, Knight Frank noted. In the first half of 2025, digital investments totalled RM42.6bil versus RM66.2bil in the similar period last year, with over 70% allocated to data centres and cloud infrastructure. While Johor continues to lead in data centre development, Klang Valley has also seen healthy activity.
Malaysian Reserve
13 hours ago
- Malaysian Reserve
Excellos, Lonza, and Akadeum Life Sciences Unite to Advance Cell Therapy Manufacturing Through Enhanced Starting Material Quality
ANN ARBOR, Mich., Aug. 6, 2025 /PRNewswire/ — Excellos, Lonza, and Akadeum Life Sciences today announce a new project aimed at redefining standards for cell therapy manufacturing by elevating the role of starting material quality. This project brings together leaders in donor cell characterization, automated manufacturing, and cell separation technology to explore how aligned, modular innovation can streamline workflows and improve outcomes across the cell and gene therapy (CGT) landscape. Together, the companies are working to spotlight the value of flexible, integrated platforms—from donor sourcing through manufacturing. The project is intended to emphasize how upstream quality impacts downstream performance, and clinical consistency. Excellos brings its donor-to-dose capabilities—including donor management, apheresis, cell characterization, and GMP manufacturing—while Akadeum contributes its gentle, flotation-based cell separation technology and Lonza offers the Cocoon® Platform, a functionally closed, automated manufacturing system enabling decentralized scale-up. While early conversations are exploring the technical feasibility of combining these approaches into a single modular workflow, the immediate focus is on sharing best practices and aligned innovation strategies across upcoming industry events. These include an August 12 symposium hosted at Excellos' San Diego headquarters and a joint webinar on August 21 titled: Unlocking Upstream Value: Donor-to-Dose Solutions for Scalable Cell Therapy Manufacturing. The August 12 symposium will feature expert panels co-hosted by Excellos, Teknova, and Pluristyx, covering topics like supply chain risk, regulatory evolution, and emerging tools like AI and machine learning in CGT operations. The August 21 webinar will bring together scientific experts from the three organizations to discuss how upstream choices surrounding donor sourcing, apheresis processing, cell selection and automated manufacturing affect therapeutic performance, reduce variability, and improve scale-up for both autologous and allogeneic therapies. The discussion will walk through the science and tools required to build robust, patient-informed cell and gene therapy solutions. 'Quality at the starting point is not optional—it's foundational,' said Rob Tressler, CSO of Excellos. 'When you bring together deeply characterized donor material, gentle cell selection, and functionally closed-system manufacturing, you set the stage for scalable and consistent therapies.' 'Our microbubble technology was built for cell health,' said Bill Lloyd, PhD, Senior Director of R&D at Akadeum. 'Exploring how our kit performs within an automated environment like the Cocoon® Platform is part of an exciting vision to scale up without compromising cell quality.' 'Lonza is proud to be part of this conversation and collaboration,' added Glen Prosise, PhD, MBA, Senior Sales and Applications Manager at Lonza. 'The Cocoon® Platform is designed for integration—and it's exciting to explore how these technologies can work in concert in a way that's intended to help reduce variability and accelerate therapeutic timelines.' The collaboration is rooted in a shared belief: better inputs lead to better therapies. Over the coming months, the companies intend to explore opportunities for deeper technical integration and data-sharing that supports industry-wide advancement in cell therapy manufacturing. To register for the symposium: August 12, 2025 Cell Therapy Manufacturing Symposium at Excellos HQTo attend the webinar: Donor-to-Dose Solutions for Scalable Cell Therapy Manufacturing Media Contacts:Akadeum: Brandon McNaughtoninfo@ Excellos: Jessica Wanamaker jwanamaker@
